AbobotulinumtoxinA and rehabilitation vs rehabilitation alone in post-stroke spasticity: A cost-utility analysis
Carlo Lazzaro, Alessio Baricich, Alessandro Picelli, Patrizia Maria Caglioni, Marco Ratti, Andrea Santamato
Studio di Economia Sanitaria, Via Stefanardo da Vimercate, IT-20128 Milan, Italy. E-mail: email@example.com
Objective: To investigate costs and quality-adjusted life years of rehabilitation combined with abobotulinumtoxinA (aboBoNT-A) (rehab/aboBoNT-A) vs rehabilitation alone (rehab) in post-stroke spasticity in Italy.
Design: Based on both Italian National Health Service and societal perspectives, a 2-year cost-utility analysis model was performed.
Subject/patients: The cost-utility analysis model considered hypothetical patients.
Methods: The cost-utility analysis model was populated with data concerning demographics, disease severity, healthcare and non-healthcare resource consumption. Data were collected via a questionnaire administered to 3 highly experienced Italian physiatrists (864 out of 930 post-stroke spasticity patients on rehab/aboBoNT-A in total). Costs are expressed in Euro (€) based on the year 2018.
Results: The cost to society (rounded to the nearest whole €) was €22,959 (rehab/aboBoNT-A) vs €11,866 (rehab). Italian National Health Service-funded cost was €7,593 (rehab/aboBoNT-A) vs €1,793 (rehab). Over a period of 2 years rehab/aboBoNT-A outperforms rehab in terms of quality-adjusted life years gained (1. 620 vs 1. 150). The incremental cost-utility ratio was €12,341 (Italian National Health Service viewpoint) and €23,601 (societal viewpoint). Sensitivity analyses confirmed the robustness of the baseline results.
Conclusion: Despite some limitations, the higher number of quality-adjusted life years gained vs rehab and the high probability of reaching a cost-utility ratio lower than the Italian informal acceptability range (€25,000–40,000) make rehab/aboBoNT-A a cost-effective healthcare programme for treating patients with post-stroke spasticity in Italy.
Using a tool named cost-utility analysis, this study investigated whether rehabilitation combined with a given drug (abobotulinumtoxinA) for post-stroke spasticity is cost-effective (i.e. affordable) vs rehabilitation alone for both the Italian National Health Service and society. Over a period of 2 years, this study shows that each additional year weighted for health-related quality of life (quality-adjusted life year; QALY) gained via rehabilitation combined with abobotulinumtoxinA vs rehabilitation alone for post-stroke spasticity costs the Italian National Health Service and society €12,341 and €23,601, respectively (2018 values). Given the Italian informal acceptability range (i.e. the maximum amount decision-makers are supposed to pay) for additional QALY gained (€25,000–40,000), these results support the conclusion that rehabilitation combined with abobotulinumtoxinA is a cost-effective (i.e. good value for money) healthcare programme for treating patients with post-stroke spasticity in Italy.
Do you want to comment on this paper? The comments will show up here and if appropriate the comments will also separately be forwarded to the authors.
You need to login/create an account to comment on articles. Click here to login/create an account